PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Pipeline portfolio • Phase III pipeline portfolio: Global CNS disorders therapeutics market • Phase II pipeline portfolio: Global CNS disorders therapeutics market • Phase I pipeline portfolio: Global CNS disorders therapeutics market • Pre-clinical and discovery pipeline portfolio: Global CNS disorders therapeutics market PART 06: Market landscape • Market overview • Five forces analysis PART 07: Market segmentation by type of disease • Global depression drugs market • Global MS drugs market • Global schizophrenia drugs market • Global bipolar disorder therapeutics market • Global AD drugs market • Global epilepsy drugs market • Global PD drugs market PART 08: Geographical segmentation • CNS disorders therapeutics market in Americas • CNS disorders therapeutics market in EMEA • CNS disorders therapeutics market in APAC PART 09: Market drivers • Special regulatory designations for CNS disorders • New DMD approvals for AD, PD, and MS • Development of novel therapeutics using innovative technologies • High growth potential of mAbs PART 10: Impact of drivers PART 11: Market challenges • High failure rates of late-stage products in clinical trials • Growing use of non-invasive neuromodulation and seizure management devices • Unavailability of standard diagnostic methods • Increase in rehabilitation programs • Social stigma associated with CNS diseases PART 12: Impact of drivers and challenges PART 13: Market trends • Popularity of me-too drugs • Increased uptake of new-generation drugs • Reformulation of marketed drugs • Focus on regenerative therapies for CNS disorders • Increase in use of LAI antipsychotics PART 14: Vendor landscape • Competitive scenario • Key news3 • GlaxoSmithKline7 • Pfizer • Eli Lilly • Janssen Pharmaceuticals • Novartis • Other prominent vendors PART 15: Appendix • List of abbreviations PART 16: Explore Technavio

GlaxoSmithKline, Pfizer, Eli Lilly, Janssen Pharmaceuticals, and Novartis. Other Prominent Vendors in the market are: AB Science, AbbVie, Abital Pharma, Acorda Therapeutics, Active Biotech, Adamas Pharmaceuticals, Addex Therapeutics, Akorn, Alcobra, Alexza Pharmaceuticals, Alkermes, Amarantus, Aprecia Pharmaceuticals, Archer Pharmaceuticals, Astellas, AstraZeneca, Aurobindo Pharma, Auspex Pharmaceuticals, Avanir Pharmaceuticals, Biscayne Pharmaceuticals, Boehringer Ingelheim, Cerecor, Concordia, Convergence Pharmaceuticals, Curemark, CURx Pharmaceuticals, Dainippon Sumitomo Pharma, Dart NeuroScience, Delpor, Desitin Arzneimittel, D-Pharm, Edgemont Pharmaceuticals, Endo International, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre-Kramer Pharmaceuticals, Forum Pharmaceuticals, Gedeon Richter, Glenmark, Grupo Ferrer Internacional, GW Pharmaceuticals, H. Lundbeck, Hisamitsu, Impax, Insero Health, INSYS Therapeutics, Intellipharmaceutics, Intra-Cellular Therapies, Ipsen, Kyowa Hakko Kirin, Ligand Pharmaceuticals, Lupin, MarcoPolo Pharmaceuticals, Marinus Pharmaceuticals, Meda AB, Merck, Mitsubishi Tanabe, MSI Methylation Sciences, Mylan, Naurex, Neuralstem, Neurelis , Neurovance, Nobelpharma, Noven Pharmaceuticals, Omeros, Opexa, Opko Health, Orion, Ophelia Pharmaceutical, Otsuka Pharmaceuticals, Palobiofarma, Par Pharmaceuticals, Pierre Fabre, Pierre Fabre, Prana Biotechnology, Raptor Pharmaceutical, Reviva Pharmaceuticals , SAGE Therapeutics, Sanofi, SciFlour, Sedor Pharmaceuticals, Shire, Siena Biotech, SK Biopharmaceuticals, SOM Biotech, Somerset Pharmaceuticals, STADA Arzneimittel, Sun Pharmaceuticalc, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Suven, Takeda Pharmaceuticals, Teva Pharmaceuticals, Torrent Pharmaceuticals, Tris Pharma, Turing Pharmaceuticals, UCB, US WorldMeds, Valeant Pharmaceuticals, Zinfandel Pharmaceuticals, and Zogenix.